ConvaTec Group PLC
SWB:2CV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.8T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.9B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
35.5B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
122.3B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
11.7B USD |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.2B CNY |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.3T KRW |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.2B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
ConvaTec Group PLC
Glance View
ConvaTec Group PLC is a notable player in the realm of medical products and technologies, deftly weaving its narrative within the healthcare industry. Founded in 1978, the company has steadily established itself through strategic expansion and innovation, focusing on improving the lives of patients and enhancing healthcare delivery. The company's core business revolves around four main product categories: Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Each of these sectors is backed by a robust commitment to research and development, allowing ConvaTec to deliver specialized products that cater to both specific patient needs and broader healthcare system demands. ConvaTec's financial model centers around providing essential, high-quality medical solutions that ultimately support improved patient outcomes. The company garners revenue by partnering with hospitals, healthcare providers, and direct consumer channels, ensuring its products reach where they are most needed. With a global footprint spanning multiple continents, ConvaTec not only distributes its products widely but also adapts its strategy to meet the nuanced requirements of diverse markets. By aligning itself closely with caregivers and leveraging cutting-edge technology, the company maintains a sustainable economic engine through both recurring sales from consumables and long-term relationships with its institutional clients.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for ConvaTec Group PLC is 12.4%, which is above its 3-year median of 7.9%.
Over the last 3 years, ConvaTec Group PLC’s Net Margin has increased from 4.7% to 12.4%. During this period, it reached a low of 3.7% on Dec 31, 2022 and a high of 12.6% on Jun 30, 2025.